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Background
Severe early-onset fetal growth restriction (FGR) predisposes to fetal death, neonatal death, neonatal morbidity and neurodisability. The use of placental biomarkers has been proposed for risk stratification in pre-eclampsia, but they could be equally useful in fetal growth restriction in aiding management.
Objective
To determine the efficacy of angiogenic biomarkers at predicting adverse pregnancy outcome in severe early-onset fetal growth restriction. 
Study Design
This is a secondary analysis of the multicentre, placebo-controlled STRIDER UK randomised controlled trial of singleton pregnancies with severe early-onset fetal growth restriction. 
Women with FGR pregnancies between 22+0 and 29+6 weeks of gestation were randomly assigned to receive either sildenafil 25 mg three times daily or placebo until 32+0 weeks’ gestation or delivery. We developed prediction models based upon maternal demographics (age, parity, blood pressure, preeclampsia, gestational hypertension), fetal biometric (estimated fetal weight) and Doppler measurements (Middle Cerebral Artery (MCA), Umbilical Artery (UA)) and maternal angiogenic biomarkers [placental growth factor (PlGF), soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt-1) and sFlt-1:PlGF ratio) using both univariate and multivariate analysis. 
Results
A complete data set was available for 105 of 135 randomised women. Multivariate regression analysis identified estimated fetal weight (EFW) and sFlt-1:PlGF as independent predictors of livebirth (EFW OR: 1.01 (1.008, 1.021); p<0.001 and lower sFlt-1:PlGF ratio OR: 0.53 (0.284, 0.994); p=0.048) and overall survival (EFW OR: 1.01 (1.006, 1.015); p<0.001 and lower sFlt-1/PlGF ratio OR: 0.51 (0.286, 0.904); p=0.021). EFW was a consistent predictor for all outcomes other than gestation at delivery. sFlt-1:PlGF ratio was a consistent predictor for all outcomes other than neonatal morbidity. 
Conclusions
In severe early-onset FGR pregnancies livebirth and overall survival can be predicted using a model involving EFW and sFlt-1:PlGF ratio. This model require validation in a larger cohort but will may allow informed decision making about pregnancy management, especially in previable cases that may be considered previable.
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Introduction
Severe early-onset fetal growth restriction (FGR) is associated with significant adverse pregnancy outcomes; fetal and neonatal death ADDIN EN.CITE 1-3, necrotizing enterocolitis3, respiratory complications3, neurodisability ADDIN EN.CITE 4-7 and lifelong health risks for the child ADDIN EN.CITE 8-10. Currently, there is no effective treatment for severe early-onset FGR with women being offered a choice of; 1) expectant management with intensive surveillance and iatrogenic preterm delivery or 2) termination of pregnancy if available ADDIN EN.CITE 11. 
We conducted a randomised controlled trial (RCT) to test the hypothesis that sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, could prolong gestation by improving the blood supply to the placental bed12. However, our RCT demonstrated no evidence of  benefit in either short-term fetal or neonatal outcomes in those women treated with sildenafil13. Despite these negative findings, the STRIDER UK RCT does provide valuable clinical and biomarker information for early-onset FGR pregnancies with a more extreme phenotype than other previously published cohorts ADDIN EN.CITE 1, 11.
Risk stratification on which to base a prognosis for the pregnancy, such as the likelihood of the fetus being born alive or surviving the neonatal period is currently lacking. This may be particularly pertinent when the diagnosis of FGR is made at extremely early gestations when viability is uncertain.
Published FGR cohorts such as the TRUFFLE study provide data on the risk of perinatal mortality and neurological impairment at 2 years of age in pregnancies with moderate to severe FGR ADDIN EN.CITE 7, 11. The TRUFFLE study demonstrated that the risk of fetal demise is actually very low (<2%) in fetuses with an estimated fetal weight (EFW) is >500g and an abnormal umbilical artery Doppler (raised PI or worse) when management is led by a fetal medicine expert guided by ultrasound and computerized CTG. Another large cohort of severe early-onset FGR fetuses, classified as previable, showed a perinatal mortality of 52% (111/212, after excluding terminations) and a diagnosis to delivery interval of 8.1 weeks for survivors ADDIN EN.CITE 1. Unfortunately, neither of these studies had information on placental biomarkers. 
With regards to prediction of FGR, the most effective biomarker to date appears to be placental growth factor (PlGF)  ADDIN EN.CITE 14-17. A panel of angiogenic biomarkers, including PlGF and soluble fms-like tyrosine kinase 1 (sFlt-1), measured at 24-28 weeks of gestation appears to be a good predictor of subsequent fetal demise (Relative risk of 29.1) when grossly abnormal ADDIN EN.CITE 18 a feature that persists at later gestations ADDIN EN.CITE 19. A recent large cohort study investigating the use of routine third trimester ultrasound screening had a minimal impact on stillbirth20 but when combined with sFlt-1/PlGF would have reliably predicted FGR at 28 weeks (Positive Likelihood Ratio [LR+] 41.1, Sensitivity 38.5%, Specificity 99.1% and Positive Predictive Value [PPV] 21.3%) and predicted delivery of an FGR baby with associated preeclampsia or perinatal morbidity when performed at 36 weeks (LR+ 17.5%, Sensitivity 37.9%, Specificity 97.8% and PPV 21.6%) 21. Small cohort studies in early onset FGR populations have confirmed this association with abnormal sFlt-1/PlGF ratio  ADDIN EN.CITE 22, 23.
In light of the promising data from small studies on biomarker prediction  ADDIN EN.CITE 22, 23 and the significant pathology in our STRIDER UK cohort, we hypothesized that a prediction model based upon measurable clinical features on ultrasound and biomarkers for placental disease in a population of fetuses with severe early-onset FGR could be beneficial to aid decision making by women and clinicians.

Materials and Methods
This is a secondary analysis of the association between fetal biometric measurements, Doppler indices and maternal angiogenic biomarkers at the time of diagnosis of severe early-onset FGR with pregnancy outcome from the STRIDER UK trial13.
STRIDER UK is a multicentre RCT of sildenafil vs placebo for the treatment of severe early-onset FGR defined as a singleton pregnancy between 22+0 and 29+6 weeks of gestation with; i) a fetus with an abdominal circumference (AC) or EFW below the 10th centile and ii) absent or reversed end diastolic flow (EDF) in the umbilical artery on Doppler velocimetry. Gestation was determined by first trimester crown rump length.
Following informed consent and biometry assessment women were randomised to receive sildenafil or placebo (25 mg three times per day) until 32+0 weeks of gestation or delivery, with the clinical management and decision to deliver determined by the attending clinical team. Doppler, growth and blood pressure were assessed a minimum of weekly by a fetal medicine specialist. Blood samples were taken prior to treatment and at regular points over the following 2 weeks after randomization. There was no change in angiogenic blood parameters over time as demonstrated by the fitting of longitudinal models and assessing the slope term (data not shown). As no change was observed, only blood biomarkers from the time of diagnosis of FGR have been considered for this analysis. The use of Sildenafil was also included in these models and the change in angiogenic markers showed no difference between treatment arms. 
Doppler ultrasound was performed serially in four vessels; the umbilical artery (UA), middle cerebral artery (MCA), ductus venosus (DV) and uterine artery (UtA). In addition to the Pulsatility Index (PI), UA EDF, DV a-wave and the presence of bilateral UtA notching were recorded. Abnormal Doppler findings were defined as follows; for UA raised PI (>95th centile), absent EDF, or reversed EDF; for MCA low PI (<5th centile); for DV a-wave absent or reversed, and for UtA mean PI >1.45 or bilateral notching.
Serum samples (≥2 ml) collected at the time of diagnosis of FGR and prior to treatment were analyzed retrospectively. Maternal serum concentrations of sFlt-1 and PIGF (pg/ml) were determined using the automated Elecsys® electro-chemiluminescence immunoassay platform (Roche Cobas, Mannheim, Germany) and used to calculate sFlt-1:PlGF ratios. Maternal serum concentrations of soluble endoglin (sEng) (ng/ml) were determined using human Quantikine® enzyme-linked immunosorbent assays (R&D Systems, Minneapolis, MN, USA). 

Statistical Methodology
Univariate and Multivariable generalized linear models were used to assess the impact of clinical covariates and biomarkers on neonatal outcomes.  All continuous clinical covariates at randomization and categorical clinical covariates with sufficient frequencies to be discriminatory (at least 5 observations in each category) were included in the univariate analysis; gestational age, gestational hypertension, preeclampsia, EFW, blood pressure (systolic and diastolic), mean arterial pressure (MAP) and parity. Doppler covariates included UA EDF, DV a-wave, MCA PI and UtA notching. Biomarker data included PlGF, sFlt-1, sEng and sFlt-1:PlGF ratio. EFW was included in the model as it was observed. Models were explored that included gestational age with EFW, gestational age alone, and EFW corrected for gestational age (e.g. As a Z-score or the expected EFW for the gestational age).  However, the best model performance was for the model which included EFW alone. Gestational age was measured in days and then converted into weeks for clarity of presentation.  No precision or granularity was lost in this conversion.
Analyses were carried out on five clinical outcomes; livebirth, gestation at delivery, overall survival, neonatal morbidity and birth weight. Overall survival was defined as a hospital discharge of a live child. Neonatal morbidity was defined as a liveborn fetus surviving to discharge and experiencing at least one of the following adverse outcomes: necrotizing enterocolitis, retinopathy of prematurity, bronchopulmonary dysplasia requiring oxygen therapy at 36 weeks, patent ductus arteriosus requiring medical or surgical treatment, the need for vasopressor therapy, neonatal infection, intraventricular hemorrhage (IVH) within 6 weeks of delivery or a confirmed serious adverse event (SAE) as defined by the STRIDER UK protocol13. 
Univariate analyses and multivariate analyses were carried out using a generalized linear modelling approach assuming a Gaussian family with identity link for continuous outcomes and a binomial family with logistic link for categorical outcomes. All terms included were considered as candidate covariates in the multivariate analysis. Selection of terms in multivariate models were performed using a forward stepwise approach evaluated using Akaikes Information Criterion (AIC). Continuous covariates were evaluated graphically and models produced which included both raw and transformed data. The models themselves were constructed using a forwards stepwise procedure with other ‘plausible alternatives’ also explored by adding and removing terms and assessing model parameters to assess if any multicolinearity was having any adverse effect on the models. A forward approach was chosen over a backwards approach to avoid over-parameterized models which would include a large number of candidate covariates. Values of PlGF, sFlt-1, sEng, and sFlt-1:PlGF ratio were included as covariates measured on the log scale to account for extreme value observations. The distribution of all angiogenic markers were assessed following transformation to ensure they were appropriately distrusted for further analysis.  Reported results were presented in terms of odds ratios (95% CI) for categorical data and mean (95% CI) estimates for continuous outcomes. Interval validation of the final model for each outcome was carried out using a bootstrap approach using measures of discrimination and calibration. Graphical summaries present the predicted model results along with all analyses are carried out using the statistical package R (Version 3).

Results
Study Population
One hundred and thirty five women were recruited to the STRIDER UK trial between November 2014 and July 2016 from 19 fetal medicine units within the UK. The study population available for analysis was 105 (77.8%) women (Table 1); data for 30 of the recruited women was removed as angiogenic biomarker information was unavailable. Sixty one (58%) women were recruited before 26+0 weeks and 44 (42%) between 26+0 and 29+6 weeks of gestation. Of the 105 available participants, 70/105 (67%) babies were born alive and 59/105 (56%) were discharged alive. 46/70 (66%) liveborn babies experienced neonatal morbidity. The median (IQR) gestation at delivery was 28.3 (26.9, 29.7) weeks and the median (IQR) birth weight was 590g (480, 769).
Modelling
The results of univariate analysis for each of the five outcomes are included in Table 2. Considering clinical covariates, EFW at randomization (considered synonymous with confirmation of diagnosis of FGR) and gestation at randomization were consistent univariate predictors for all outcomes. Preeclampsia was a univariate indicator of a lower gestational age at delivery (est [se] = -1.06 [0.506]; p-value =0.038).  Reversed UA EDF Doppler (est [se] = -1.08 [0.417]; p-value =0.011) was a univariate indicator of gestation at delivery. All four biomarker measures (PlGF, sEng, sFlt-1 and sFlt-1:PlGF ratio) were univariate indicators of gestation at delivery and birth weight. UtA Doppler was also a significant indicator for birth weight. PlGF and the sFlt-1:PlGF ratio were significant univariate indicators of livebirth and overall survival.
The results of the selected univariate modelling are included in Table 2. The results of multivariate modelling are included in Table 3 and include model intercepts for completeness. The results for each outcome are discussed separately.

Livebirths: As EFW increased, the odds of a live birth also increased [OR: 1.01 (1.008, 1.021); p-value <0.001] per gram of EFW.  A lower sFlt-1:PlGF ratio [OR: 0.53 (0.284, 0.994); p-value = 0.048] was associated with a larger probability of overall neonatal survival. In terms of measuring the importance of each covariate, EFW can be shown to explain 40% of the model variability whereas sFlt-1:PlGF ratio explains 4%. The intercept of 0.14 (0.003, 7.39) allows estimation of the probability of a live birth (Figure 1A, B). This data is also represented as a receiver operating characteristic (ROC) curve with an area under the curve (AUC) of 0.90 (Figure 1C). For example; for a fetus with an estimated fetal weight of 400g and a (log) sFlt-1:PlGF ratio of 4,  the estimated probability of a live birth would be 37% as shown below.



Gestation at birth: The presence of pre-eclampsia reduced the gestation at birth by almost a week [Est: -0.97 (-1.8, -0.2); p-value = 0.020] whilst having a later gestational age at randomization delayed the gestation at birth [Est: 0.61 (0.5, 0.7); p-value <0.001]. Regarding Doppler measurement, the presence of reversed EDF in the umbilical artery [Est: -0.97 (-1.6, -0.3); p-value <0.001] resulted in an earlier gestation at delivery. With respect to biomarker data, a higher sFlt-1:PlGF ratio [Est: -0.6 (-0.8, -0.3); p-value < 0.001] led to an earlier gestation at delivery.

Overall survival: As EFW increased, the odds of overall survival increased [OR: 1.01 (1.006, 1.015); p-value <0.001]. A lower sFlt-1:PlGF ratio [OR: 0.51 (0.286, 0.904); p-value = 0.021] was also associated with a larger probability of overall survival. Figure 2 shows the relationship between EFW and sFlt-1:PlGF ratio at diagnosis and survival. A graphical representation of the model results is also provided to give predicted probabilities of overall survival based on EFW and sFlt-1:PlGF ratio (Figure 2A, B). This data is also represented as a ROC curve with an AUC of 0.88 (Figure 2C)

Neonatal Morbidity:  The only covariate chosen for inclusion in the multivariate model of neonatal morbidity was EFW. As EFW increased the probability of neonatal morbidity decreased [Est: 0.99 (0.994, 0.999); p-value = 0.002].

Birth Weight:  Birth weight was greater if the EFW [Est: 1.38 (1.14, 1.61); p-value <0.001] at first scan was larger. However, if the gestation at first scan was higher there was a negative impact on birth weight [Est: -26.62 (-49.64, -3.61); p-value = 0.026].  Considering clinical characteristics, primiparity was associated with a greater birth weight [Est: 66.36 (15.67, 117.05); p-value = 0.012].  Considering biomarker covariates, an increased level of sEng [Est: 61.94 (12.72, 111.15); p-value = 0.015] was associated with greater birth weight whereas an increased sFlt-1:PlGF ratio [Est: -119.43 (-151.94, 86.93); p-value < 0.001] was associated with lower birth weight.  

For the models predicting birth status, overall survival and neonatal morbidity EFW is included as a predictive covariate as measured (e.g. not adjusting for gestational age). Models were explored that included gestational age with EFW, gestational age alone, and EFW corrected for gestational age (e.g. As a Z-score or the expected EFW for the gestational age).  However, the best model performance was for the model that included EFW, so other ways to express fetal weight are not included in the reported models.  However, recognizing that gestational age is an important predictor of long term neonatal outcome, model investigations were performed replacing EFW at randomization with gestation at randomization. EFW and gestation are highly correlated (Pearson’s correlation = 0.87). A comparison of the models are given in the supplementary information (Table S1). This demonstrates that a model including gestational age at randomization has both a larger model deviance (104.9 compared to 89.0) and a smaller measure of concordance (c-statistic) (0.88 compared to 0.83) and thus the model including EFW rather than gestational age at randomization has a better model fit. The impact of the sFlt-1:PlGF ratio did not materially change between the two models. A further summary of the internal validation used to assess the performance of each model is included in the supplementary information (Table S2).

DISCUSSION
Principal Findings
Our study has confirmed that the combination of clinical biometric data routinely recorded in cases of early-onset FGR and sFlt-1:PlGF ratio can predict pregnancy outcome for both livebirth, gestation at delivery, birthweight and overall survival. Other covariates also showed benefit in predicting gestation at delivery and birth weight. EFW was a consistent predictor for all outcomes other than gestation at delivery. sFlt-1:PlGF ratio was a consistent predictor for all outcomes other than neonatal morbidity.

Results
To date the majority of published data have demonstrated that a low PlGF or raised sFlt-1:PlGF ratio are associated with a greater likelihood of stillbirth ADDIN EN.CITE 16, 24-27 or adverse pregnancy outcome ADDIN EN.CITE 28 and is associated with fetal growth restriction ADDIN EN.CITE 2, 17, 21, 29-33 and placental pathology ADDIN EN.CITE 16. A recent Cochrane Diagnostic Test Accuracy Review on the effectiveness of biomarkers to predict stillbirth calculated that an abnormal PlGF or sFlt-1:PlGF ratio have a diagnostic odds ratio of 49.2 for subsequent stillbirth 34. Our data appears to corroborate the accuracy of sFlt-1:PlGF ratio for predicting adverse pregnancy outcome with livebirth and overall survival having an AUC of 0.90 and 0.88 respectively.
This finding is logical as a poorly functioning placenta would be expected to have associated angiogenic factor dysfunction as observed in preeclampsia  ADDIN EN.CITE 17, 27. The fact that in pregnancies affected by severe early-onset FGR this finding can be used to estimate pregnancy outcome is, however, novel. 

Clinical Implications
The strength of our model is that it combines the diagnostic sensitivity of the sFlt-1:PlGF ratio with the routinely collected clinical covariates of EFW and gestational age to determine likelihood of livebirth and overall survival. 
The results of this study cannot readily be generalized beyond our inclusion criteria to other high risk pregnancy situations or late-onset FGR, and would need to be further validated within an FGR population. However, within the context of severe early-onset FGR we feel that providing a predictive assessment of outcome will be of significant value to clinicians and parents

Research Implications
Several small cohort studies have shown an association between early onset FGR and abnormal sFlt-1/PlGF ratio  ADDIN EN.CITE 22, 23. A recent large prospective cohort was also able to use this biomarker to predict subsequent delivery with a FGR fetus but in a low risk unselected population 21. Due to the close association between pregnancy outcome and PlGF or sFlt-1:PlGF ratio it is perhaps unsurprising that we identified no effect from the use of the angiogenic markers sEng or sFlt-1 alone. Further research would potentially clarify the role of these biomarkers in pregnancy prediction.

Strengths and Limitations
This study is not the first to study the predictive capacity of angiogenic biomarkers to predict adverse pregnancy outcome in severe early-onset FGR but does present a more detailed assessment of risk than has previously been performed. As such it has significant value in being able to guide clinicians and parents’ decision making about the management of these high risk pregnancies. The prospective collection of rare and highly phenotyped cases managed within a single healthcare structure is unique.
This study has some limitations. Firstly some covariates (DV A-wave, UA PI) were not considered for inclusion in the modelling as the distribution of patients in these groups would not allow for reliable model estimates. Secondly, we did not mandate a clinical management pathway for FGR, which may mean that women were managed differently between units. However, we would anticipate that the impact of this is minimal due to the large number of units all of whom would be guided by the national guidance within the UK 35.

Conclusion
This is the first time sFlt-1:PlGF ratio has been performed prospectively on a cohort of pregnancies complicated by severe early-onset FGR and correlated with a risk of adverse outcome in a prediction model. Use of this model may aid clinicians in determining the timing of fetal assessment and monitoring, timing of delivery, place of birth and may provide useful guidance for appropriate use of neonatal services. However, the main benefit of this model is likely to be in guiding the counselling of parents and families in the likelihood of a good outcome for their child. 
Further large cohort studies will be required to confirm the benefits of validate this prediction model in severe early-onset FGR and as a predictive test for adverse pregnancy outcome including both short and long term physical and neurodevelopmental outcomes for the child.
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Figure Legends

Figure 1: Birth status by estimated fetal weight and sFlt-1:PlGF ratio at diagnosis. Data presented in graphical form denoting probability (95% CI) of a live birth (green denoted higher probability) (A), scatter graph of raw data (B) and ROC curve (C).

Figure 2: Overall survival (discharged alive – green and perinatal mortality - red) by estimated fetal weight and sFlt-1:PlGF ratio at diagnosis. Data presented in graphical form denoting probability (95% CI) of a live discharge (green denoted higher probability) (A), scatter graph of raw data (B) and ROC curve (C).

Table 1: Demographic data for the STRIDER UK study cohort.

Table 2: Univariate analysis for five clinical outcomes (Livebirth, Gestation at Birth (weeks), Overall Survival, Neonatal Morbidity and Birth Weight (grams).

Table 3: Multivariate analysis for five clinical outcomes (Livebirth, Gestation at Birth (weeks), Overall Survival, Neonatal Morbidity and Birth Weight (grams).

Table S1: Internal validity testing using comparison of EFW and Gestation at randomization.

Table S2: Results of internal validation of predictive models



